Equities research analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to announce sales of $491.02 million for the current quarter, Zacks reports. Four analysts have provided estimates for IDEXX Laboratories’ earnings, with the lowest sales estimate coming in at $487.10 million and the highest estimate coming in at $494.68 million. IDEXX Laboratories reported sales of $443.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.8%. The firm is scheduled to announce its next earnings results before the market opens on Thursday, February 1st.
According to Zacks, analysts expect that IDEXX Laboratories will report full year sales of $491.02 million for the current fiscal year, with estimates ranging from $1.95 billion to $1.96 billion. For the next financial year, analysts anticipate that the business will report sales of $2.16 billion per share, with estimates ranging from $2.14 billion to $2.18 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. IDEXX Laboratories’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the business earned $0.62 EPS.
In related news, CEO Jonathan W. Ayers sold 2,160 shares of IDEXX Laboratories stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total transaction of $360,784.80. Following the transaction, the chief executive officer now owns 1,077,112 shares in the company, valued at approximately $179,910,017.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. Insiders have sold a total of 130,160 shares of company stock worth $20,019,685 in the last 90 days. Company insiders own 2.77% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. National Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 2.1% during the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock valued at $332,000 after acquiring an additional 42 shares in the last quarter. Advisor Group Inc. increased its stake in IDEXX Laboratories by 1.1% during the 2nd quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock worth $732,000 after buying an additional 52 shares during the period. QS Investors LLC increased its stake in IDEXX Laboratories by 1.5% during the 2nd quarter. QS Investors LLC now owns 4,068 shares of the company’s stock worth $657,000 after buying an additional 60 shares during the period. Thrivent Financial For Lutherans increased its stake in IDEXX Laboratories by 3.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 3,340 shares of the company’s stock worth $539,000 after buying an additional 100 shares during the period. Finally, Ropes Wealth Advisors LLC increased its stake in IDEXX Laboratories by 4.1% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 5,040 shares of the company’s stock worth $814,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 86.66% of the company’s stock.
IDEXX Laboratories (NASDAQ IDXX) opened at $180.63 on Friday. The firm has a market cap of $15,754.37, a price-to-earnings ratio of 58.46, a price-to-earnings-growth ratio of 2.43 and a beta of 0.42. IDEXX Laboratories has a 1-year low of $116.54 and a 1-year high of $180.88. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $491.02 Million” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3148808/zacks-analysts-expect-idexx-laboratories-inc-idxx-will-announce-quarterly-sales-of-491-02-million.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.